Lab Review: Interpretation and Management
Your labs show Stage 3a chronic kidney disease (CKD) with moderate renal insufficiency (eGFR 59 mL/min/1.73 m²), while the anion gap of 10.9 is actually normal by modern measurement standards, and the MCHC/MPV findings are minor red blood cell variations that require no immediate action.
eGFR 59 mL/min/1.73 m² - Stage 3a CKD
This is the most clinically significant finding requiring action.
Classification and Risk
Your eGFR places you in Stage 3a CKD (moderately decreased GFR: 45-59 mL/min/1.73 m²) 1. According to KDIGO classification, without knowing your albuminuria status, you fall into at minimum the "moderate risk" category 1.
Required Actions:
- Check urine albumin-to-creatinine ratio (UACR) immediately if not already done - this is essential for complete risk stratification 2, 3
- Annual monitoring minimum: Repeat eGFR and UACR at least once yearly, potentially more frequently depending on progression rate 4
- Blood pressure control: Target <140/90 mmHg 5
- Consider nephrology referral if: UACR >60 mg/mmol, evidence of progression (>5 mL/min/1.73 m² decline per year), or drop to eGFR <45 mL/min/1.73 m² 2, 5
Medication Considerations:
- Review all medications for renal dosing adjustments - many drugs require dose modification at eGFR <60 5
- If you have diabetes and/or albuminuria, ACE inhibitors or ARBs are preferred for blood pressure management 3
- Consider SGLT-2 inhibitors if you have diabetes or significant albuminuria, as these reduce CKD progression and cardiovascular events 1, 2
Monitoring for Progression:
Watch for decline in GFR category with ≥25% drop from baseline, or rapid progression defined as sustained decline >5 mL/min/1.73 m²/year 4, 5. Small fluctuations are common and don't necessarily indicate true progression 4.
Anion Gap 10.9 - NORMAL
This is not high. Modern ion-selective electrode methodology has shifted the normal anion gap reference range from the old 12±4 mEq/L down to 3-11 mEq/L or 6±3 mEq/L 6, 7, 8. Your value of 10.9 falls within the current normal range.
Key Point:
Many clinicians and older textbooks still reference the outdated range of 8-16 mEq/L, leading to misinterpretation 7. A truly elevated anion gap by modern standards would be >12 mEq/L, with values >24 mEq/L being rare and highly significant 7. Your value requires no intervention.
MCHC 31.4 g/dL (Low) and MPV 12.5 fL (High)
MCHC (Mean Corpuscular Hemoglobin Concentration):
Low MCHC typically indicates hypochromic anemia, most commonly from iron deficiency. However, at Stage 3a CKD, anemia screening is not routinely recommended until eGFR drops below 30 mL/min/1.73 m² 9.
Action needed:
- Check complete blood count with hemoglobin level
- If anemic (hemoglobin low), check: serum ferritin, transferrin saturation (TSAT), vitamin B12, and folate 9
- Iron supplementation trial warranted if TSAT ≤30% and ferritin ≤500 ng/mL 9
MPV (Mean Platelet Volume):
Mildly elevated MPV (12.5 fL) is a non-specific finding that can occur with platelet activation, inflammation, or as a normal variant. In isolation without thrombocytopenia or thrombocytosis, this requires no specific action.
Priority Action Plan:
- Obtain UACR to complete CKD risk stratification
- Review current medications for renal dose adjustments
- Check blood pressure - ensure <140/90 mmHg
- Verify hemoglobin level - if low, proceed with anemia workup
- Schedule annual follow-up for eGFR and UACR monitoring
- Consider nephrology referral if UACR elevated or eGFR declining
The anion gap is normal and requires no action. Focus clinical attention on the Stage 3a CKD and its management.